| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 27.53▲ | 27.45▲ | 27.33▲ | 25.67▲ | 25.90▲ |
| MA10 | 27.50▲ | 27.34▲ | 27.01▲ | 25.27▲ | 27.35▲ |
| MA20 | 27.45▲ | 27.05▲ | 25.89▲ | 26.13▲ | 24.57▲ |
| MA50 | 27.28▲ | 25.62▲ | 25.21▲ | 27.41▲ | 20.97▲ |
| MA100 | 26.54▲ | 25.21▲ | 25.60▲ | 23.94▲ | 18.20▲ |
| MA200 | 25.64▲ | 25.78▲ | 26.95▲ | 21.26▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.003▼ | -0.002▼ | 0.186▲ | 0.126▲ | -0.164▼ |
| RSI | 59.405▲ | 68.837▲ | 70.317▲ | 57.400▲ | 62.462▲ |
| STOCH | 87.847▲ | 72.511 | 83.233▲ | 46.205 | 43.925 |
| WILL %R | -31.250 | -21.429▲ | -9.296▲ | -8.549▲ | -28.275 |
| CCI | 164.954▲ | 71.567 | 92.261 | 168.086▲ | 12.998 |
|
Tuesday, March 31, 2026 01:12 AM
PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/04/26 | 26.90 | 27.88 | 26.665 | 27.55 | 270,377 |
| 31/03/26 | 24.89 | 27.08 | 24.89 | 26.59 | 306,791 |
| 30/03/26 | 24.85 | 26.81 | 24.32 | 24.55 | 219,113 |
| 27/03/26 | 24.88 | 25.09 | 24.32 | 24.69 | 126,145 |
| 26/03/26 | 24.81 | 25.18 | 24.59 | 24.99 | 113,125 |
| 25/03/26 | 24.79 | 25.62 | 24.79 | 25.00 | 323,374 |
| 24/03/26 | 24.48 | 24.86 | 24.02 | 24.52 | 214,236 |
| 23/03/26 | 25.01 | 25.96 | 24.46 | 24.60 | 249,754 |
| 20/03/26 | 25.49 | 26.01 | 24.539 | 24.86 | 282,053 |
| 19/03/26 | 26.09 | 26.355 | 24.98 | 25.37 | 473,514 |
|
|
||||
|
|
||||
|
|